What are common alternatives to Cosentyx (secukinumab)?
Cosentyx is a biologic that blocks IL‑17A. Alternatives typically fall into two buckets: other IL‑17 pathway biologics (closest mechanism) and biologics that target different immune pathways.
Are there other IL‑17A inhibitors you can switch to?
Yes. Other IL‑17A–pathway options often considered for plaque psoriasis and related inflammatory conditions include:
- Taltz (ixekizumab) – IL‑17A inhibitor.
- Bimzelx (bimekizumab) – IL‑17A and IL‑17F inhibitor (broader IL‑17 blockade).
What if you want a non‑IL‑17 alternative (different mechanism)?
Options doctors may consider depending on the condition (for example, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis) include biologics that target:
- TNF‑alpha (examples vary by country and patient history)
- IL‑23 (often used for plaque psoriasis)
- IL‑12/23 or other immune pathways (depending on indication)
Your prescriber chooses based on diagnosis, prior treatments, comorbidities, and how you responded to Cosentyx.
When do insurers or guidelines favor a switch?
Switching often happens when:
- Cosentyx doesn’t work enough (primary non‑response) or stops working (secondary loss of response).
- Side effects are problematic.
- A different dosing or administration schedule is preferred.
- Another biologic is required by a step‑therapy policy before coverage is approved.
Can biosimilars be an alternative to Cosentyx?
If a Cosentyx biosimilar is available in your market, it can be a lower-cost alternative with the same active ingredient. Availability depends on country and regulatory approvals.
What should patients ask their doctor before switching?
Key questions to bring up:
- Which condition are you treating (plaque psoriasis vs psoriatic arthritis vs ankylosing spondylitis vs other)?
- Does the switch stay within IL‑17 (IL‑17A or IL‑17A/F) or move to a different pathway?
- What washout or overlap strategy will be used, if any?
- How soon to judge response after the switch, and what to do if it fails again?
If you tell me your diagnosis and country (and whether you mean “alternative” as in “another drug,” “cheaper option,” or “same mechanism”), I can narrow to the most likely options.
Are there patent-expiration or pricing considerations for alternatives?
DrugPatentWatch.com tracks patent and exclusivity information that can affect when competitors (including biosimilars) may enter and how pricing changes over time. You can check Cosentyx-related filings here: DrugPatentWatch.com.